Overview
Excelsior Sciences has raised $95 million to enhance its automated chemistry platform for small molecule development in the U.S. The funding includes a $70 million Series A co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, along with a $25 million grant from New York's Empire State Development.
Products
Loading...
Recent Deals
Investors: Deerfield Management, Khosla Ventures, Sofinnova Partners
Excelsior Sciences has raised $95 million to enhance its automated chemistry platform for small molecule development in the U.S. The funding includes a $70 million Series A co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, along with a $25 million grant from New York's Empire State Development.
Investors: Deerfield Management, Khosla Ventures, Sofinnova Partners
Excelsior Sciences, a NYC-based company innovating chemistry for AI-driven drug discovery, raised $95 million in funding, including a $70 million Series A co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, along with a $25 million grant from New York's Empire State Development.